Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection

For patients infected with multidrug-resistant human immunodeficiency virus type 1 (HIV-1), therapeutic options are limited. Raltegravir is a new molecule that inhibits HIV integrase. In two phase 3 studies, raltegravir was found to be superior to placebo, in the context of optimized background anti...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	The New England journal of medicine Ročník 359; číslo 4; s. 339 - 354
Hlavní autori:	Steigbigel, Roy T, Cooper, David A, Kumar, Princy N, Eron, Joseph E, Schechter, Mauro, Markowitz, Martin, Loutfy, Mona R, Lennox, Jeffrey L, Gatell, Jose M, Rockstroh, Jurgen K, Katlama, Christine, Yeni, Patrick, Lazzarin, Adriano, Clotet, Bonaventura, Zhao, Jing, Chen, Joshua, Ryan, Desmond M, Rhodes, Rand R, Killar, John A, Gilde, Lucinda R, Strohmaier, Kim M, Meibohm, Anne R, Miller, Michael D, Hazuda, Daria J, Nessly, Michael L, DiNubile, Mark J, Isaacs, Robin D, Nguyen, Bach-Yen, Teppler, Hedy
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Boston, MA Massachusetts Medical Society 24.07.2008
Predmet:	Adolescent Adult Aged Antiretroviral drugs Biological and medical sciences CD4 Lymphocyte Count Clinical trials Double-Blind Method Drug dosages Drug Resistance, Viral Drug therapy Drug Therapy, Combination Female Follow-Up Studies General aspects HIV HIV Infections - drug therapy HIV Integrase Inhibitors - adverse effects HIV Integrase Inhibitors - therapeutic use HIV Integrase Inhibitors/adverse effects/therapeutic use HIV-1 - genetics HIV-1 - isolation & purification HIV-1/genetics/isolation & purification Human health sciences Human immunodeficiency virus Human viral diseases Humans Immunologie & maladie infectieuse Immunology & infectious disease Infectious diseases Logistic Models Male Medical sciences Middle Aged Neoplasms - etiology Organic Chemicals - adverse effects Organic Chemicals - therapeutic use Organic Chemicals/adverse effects/therapeutic use Pyrrolidinones Raltegravir Potassium RNA, Viral - blood Sciences de la santé humaine Treatment Outcome Viral diseases Viral diseases of the lymphoid tissue and the blood. Aids Viral Load Immunopathology Antiretroviral agent HIV-1 virus Retroviridae AIDS Immune deficiency Lentivirus Infection Virus Medicine Resistance Integrase inhibitor Treatment Viral disease Antiviral Human immunodeficiency virus Raltegravir
ISSN:	0028-4793, 1533-4406, 1533-4406
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Popis
Shrnutí:	For patients infected with multidrug-resistant human immunodeficiency virus type 1 (HIV-1), therapeutic options are limited. Raltegravir is a new molecule that inhibits HIV integrase. In two phase 3 studies, raltegravir was found to be superior to placebo, in the context of optimized background antiviral therapy, in suppressing HIV viral load at 48 weeks (62.1% vs. 32.9%). In two phase 3 studies, raltegravir was found to be superior to placebo, in the context of optimized background antiviral therapy, in suppressing HIV viral load at 48 weeks (62.1% vs. 32.9%). Highly active antiretroviral therapy is the standard of care for patients with advanced human immunodeficiency virus (HIV) infection. 1 Combination regimens have resulted in improved survival, decreased morbidity, and cost-effective care for patients with a CD4 count of less than 350 per cubic millimeter. 2 – 8 However, viral suppression cannot always be achieved or sustained with standard treatments because of the development of viral resistance, toxic effects of drugs, or lack of adherence. 9 – 18 The majority of HIV-infected patients in whom highly active antiretroviral therapy fails have resistant viral quasispecies. 12 – 15 , 19 , 20 Cross-resistance to agents within a drug class may exhaust . . .
Bibliografia:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-General Information-1 content type line 14 ObjectType-Feature-3 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 scopus-id:2-s2.0-47949120697
ISSN:	0028-4793 1533-4406 1533-4406
DOI:	10.1056/NEJMoa0708975